688505.SH
复旦张江
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 8.38
−3.01%Year over year
Reported trailing growth
- Revenue
- -11.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- +202.5%
- Operating cash flow
- +338.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -12.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- +11.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026